The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

Nafpenzal DC Intramammary Suspension

300, 100, 100 mg/syringe Intramammary suspension

Intervet Ireland LimitedVPA10996/074/001

Main Information

Trade NameNafpenzal DC Intramammary Suspension
Active SubstancesProcaine benzylpenicillin
Dihydrostreptomycin (as the sulfate)
Nafcillin (as the sodium salt) usp
Strength300, 100, 100 mg/syringe
Dosage FormIntramammary suspension
Licence HolderIntervet Ireland Limited
Licence NumberVPA10996/074/001

Group Information

ATC CodeQJ51RC23 procaine benzylpenicillin, combinations with other antibacterials
Therapeutic ClassAntibacterial


Licence Issued01/10/1987
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportPDF Version
« Back